A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease

International Journal of Clinical Practice

Volumn 59, Issue 6, 2005, Pages 665-671

  Hansen, Age Norman ^a   Bergheim, R ^b   Fagertun, H ^c   Lund, H ^b   Moum, B ^d  

^a Harbitzallèen Legesenter ^*  (Norway)

^b ASTRAZENECA   (United Kingdom)

^c 3S Scandinavian Statistical Services AS   (Norway)

^d Oestfold Hospital Trust   (Norway)

Author keywords

Empirical treatment; Esomeprazole; GERD; Heartburn; Symptoms

Indexed keywords

ESOMEPRAZOLE; RANITIDINE; ANTIULCER AGENT; OMEPRAZOLE; PROTON PUMP;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EMPIRICAL RESEARCH; ENDOSCOPY; FEMALE; FISHER EXACT TEST; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GENERAL PRACTITIONER; HEALTH CARE COST; HEARTBURN; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NORWAY; OPEN STUDY; PARALLEL DESIGN; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; DRUG ADMINISTRATION; DRUG ANTAGONISM; LONG TERM CARE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; NORWAY; OMEPRAZOLE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; PROTON PUMPS;

EID: 23844554227     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00564.x     Document Type: Article

References (32)

1. National Institute for Clinical Excellence 2000 Guidance on the Use of Proton Pump Inhibitors (Ppis) in the Treatment of Dyspepsia. Available from http://www.nice.org.uk.
2. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51 (Suppl. 1): 24-9.
3. Lee JM, O'Morain CA. Trends in the management of gastro-oesophageal reflux disease. Postgrad Med J 1998; 74: 145-50.
4. Lambert R. Review article. current practice and future perspectives in the management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11: 651-62. 10.1046/j.1365-2036.1997.00181.x
5. Venables TL, Newland RD, Patel AC et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965-73.
6. Jones R, Hungin A, Pali S et al. Gastro-oesophageal reflux disease in primary care in Europe. Eur J Gen Pract 1995; 1: 149-54.
7. Johnssen F, Joelsson B, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987; 22: 714-8.
8. Lind T, Havelund T, Carlsson R et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.
9. Carlsson R, Dent J, Watts R et al. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119-24.
10. Smout APJM. Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 81-5. 10.1046/j.1365-2036.1997.116287000.x
11. Galmiche J-P, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease. a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-73. 10.1046/j.1365-2036.1997.00185.x
12. Holtmann G. Reflux disease: The disorder of the third millennium. Eur J Gastroenterol Hepatol 2001; 13 (Suppl. 1): S5-11.
13. Wiklund I, Bardhan KD, Müller-Lissner S et al. Quality of life during acute and intermittent treatment of gastroesophageal reflux disease with omeprazole compared with ranitidine. Results from a multi-center clinical trial. Ital J Gastroenterol Hepatol 1998; 30: 19-27.
14. Tew S, Jamieson GG, Pilowsky I, Myers J. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. Dis Esophagus 1997; 10: 9-15.
15. Hatlebakk JC, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997; 11: 365-72. 10.1046/j.1365-2036.1997.144320000.x
16. Dent J, Brun J, Fendrick AM et al. on behalf of the Genval Workshop Group. An evidence-based appraisal of reflux disease management -the Genval Workshop Report. Gut 1999; 44 (Suppl. 2): S1-S16.
17. Castell DO, Richter JE, Robinson M et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux oesophagitis. Am J Gastroenterol 1996; 91: 1749-57.
18. Corinaldesi R, Valentini M, Belaïche J et al. Pantoprazole and omeprazole in the treatment of reflux esophagitis: A European multicentre study. Aliment Pharmacol Ther 1995; 9: 667-71.
19. Hallerbäck B, Unge P, Carling L et al. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994; 107: 1305-11.
20. Mössner J, Holscher AH, Herz R, Schneider A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis: A multicentre trial. Aliment Pharmacol Ther 1995; 9: 321-6.
21. Moore RA, Wiffen P, McQuay HJ, Phillips C. Reflux oesophagitis: quantitative systematic review of the evidence of effectiveness of proton pump inhibitors and histamine agonists [online]. Available from http://www.jr2.ox.ac.uk/bandolier/bandopubs/gordf/gord.html (accessed 20 September 2002).
22. Moayyedi P, Delaney B, Katzka D, Forman D. Gastro-oesophageal reflux disease. Clin Evid 2001; 5: 311-23.
23. Lind T, Rydberg L, Kylebäck A et al. Esomeprazole provides improved acid control vs. Omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7. 10.1046/j.1365-2036.2000.00813.x
24. Röhss K, Nilsson-Claar C, Rydholm H, Nyman L. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg. Gastroenterology 2000; 118 (Suppl. 2): A20.
25. Wilder-Smith C, Röhss K, Lundin C, Rydholm H. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 2000; 118 (Suppl. 2): A22.
26. Wilder-Smith C, Röhss K, Claar-Nilsson C. Esomeprazole 40 mg provides more effective acid control than lansoprazole 15 mg. American Journal of. Gastroenterology 2001; 96 (Suppl. 9): S44.
27. Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65. 10.1111/j.1572-0241.2001.03600.x
28. Kahrilas PJ, Falk GW, Johnson DA et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomised controlled trial. Aliment Pharmacol Ther 2000; 14: 1249-58. 10.1046/j.1365-2036.2000.00856.x
29. Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
30. Lind T, Junghard O, Eklund S. Esomeprazole 20 mg compared with lansoprazole 15 mg for maintenance therapy in patients with healed erosive esophagitis. Gastroenterology 2002; 122: A199.
31. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand'therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347-54. 10.1046/j.1365-2036.2001.00943.x
32. Talley NJ, Venables TL, Green JRB et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease -a placebo-controlled trial of 'on-demand'therapy for 6 months. Eur J Gastroenterol Hepatol 2002; 14: 857-63. 10.1097/00042737-200208000-00008